TheraVectys' Lenti-HPV-07 Enrolls First Patient in Phase I/IIa Trial for HPV-Induced Cancers
TheraVectys has initiated a Phase I/IIa clinical trial for Lenti-HPV-07, an onco-therapeutic vaccine targeting cancers induced by human papillomavirus (HPV).
© Copyright 2025. All Rights Reserved by MedPath